Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has granted a conditional approval for Biogen Idec's Fampyra which improves walking disability in adult patients with multiple sclerosis (MS).
Subscribe to our email newsletter
Fampyra is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine).
Studies reveal that the sustained release formulation increases conduction of damaged nerves, which results in improved walking ability.
Fampyra can be used alone or in combination with immunomodulatory drugs.
Fampyra was developed by Acorda Therapeutics and is commercialized in the US under the trade name Ampyra (dalfampridine) Extended Release Tablets, 10mg.